Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Deza, S. (Sara) | - |
dc.creator | Maroto-García, J. (Julia) | - |
dc.creator | Tellechea, O. (Olaia) | - |
dc.creator | Orbegozo, N. (Natalia) | - |
dc.creator | Merino, J. (Juana) | - |
dc.creator | Galofre, J.C. (Juan Carlos) | - |
dc.creator | Alegre-Martinez, E. (Estibaliz) | - |
dc.creator | González, Á. (Álvaro) | - |
dc.date.accessioned | 2023-10-19T07:36:18Z | - |
dc.date.available | 2023-10-19T07:36:18Z | - |
dc.date.issued | 2023 | - |
dc.identifier.citation | Deza, S. (Sara); Maroto-García, J. (Julia); Tellechea, O. (Olaia); et al. "Clinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma". Clinica Chimica Acta. 548, 2023, 117502 | es_ES |
dc.identifier.issn | 0009-8981 | - |
dc.identifier.uri | https://hdl.handle.net/10171/67674 | - |
dc.description.abstract | Background and aims: Patients’ response to treatment in differentiated thyroid cancer (DTC) is classified according to serum thyroglobulin concentrations (Tg), usually using the American Thyroid Association guidelines and considering potential interfering anti-thyroglobulin antibodies (Ab-Tg). We aim to evaluate the clinical implications of changing Tg and Ab-Tg quantification method. Material and methods: Tg and Ab-Tg were quantified in 82 serum samples (60 from DTC patients) by Elecsys and Access immunoassays. Results: Elecsys immunoassay rendered higher values of Tg than Access: mean bias 5.03 ng/mL (95%CI:- 14.14–24.21). In DTC patients, there was an almost perfect agreement for response classification (kappa index = 0.833). Discrepancies appeared in patients with undetermined response, with a more tendency to subclassification with Access. Ab-Tg showed a poor correlation (r = 0.5394). When Elecsys cut-off was reduced to 43 IU/ mL, agreement for positive/negative classification improved from a kappa index of 0.607 to 0.650. Prospective study with personalized follow-up showed that only 6.3% of Tg results required an analytical confirmation, being confirmed 93% of them. Conclusions: Despite the biases observed, clinical impact of an analytical change is minimal in patients’ management. However, cautious and personalized follow-up period after the change is still mandatory, especially in patients with Tg levels between 0.2 and 1 ng/mL. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Thyroglobulin | es_ES |
dc.subject | Differentiated thyroid cancer | es_ES |
dc.subject | Anti-thyroglobulin antibodies | es_ES |
dc.subject | Method comparison | es_ES |
dc.subject | Immunoassay | es_ES |
dc.title | Clinical implications of changing thyroglobulin and antithyroglobulin antibodies analytical methods in the follow-up of patients with differentiated thyroid carcinoma | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the CC BY-NC license | es_ES |
dc.identifier.doi | 10.1016/j.cca.2023.117502 | - |
dadun.citation.publicationName | Clinica Chimica Acta | es_ES |
dadun.citation.startingPage | 117502 | es_ES |
dadun.citation.volume | 548 | es_ES |
dc.identifier.pmid | 37516333 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.